ClinicalTrials.gg
RecruitingNCT07047612Updated Aug 7, 2025

ICP-332 in Subjects With Non-segmental Vitiligo

A Phase 2/3 interventional study of ICP-332 Tablets and ICP-332 Placebo Tablets in Non Segmental Vitiligo, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 45 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
603
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Vitiligo with a site in China — 24 open to participants now, 29 under way, 8 of them phase 3. Vitiligo · China.

Planned enrollment
4th of 32
603 · median 150
Started
2025
with 10 others
Phase 2/3
3 of 39
2 open now
Primary completion
2029-04
later than 28 of 28 live
Registered
18th of 39
by date
Lead sponsor
1 of 39
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 39 studies in Vitiligo with a site in China, this one is the 4th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 28 of the 28 other live ones, and was the 18th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

24 of the 39 studies in Vitiligo with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Vitiligo with a site in China, or all of them as a file.
02

Study summary

This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.

03

Conditions studied

  • Non Segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥18 years and ≤75 years (Phase II portion). Male or female subjects ≥12 years of age and ≤75 years of age, adolescent subjects must weigh ≥40 kg (Phase III portion).
  2. Eligible subjects must meet all of the following criteria at screening and baseline:

    1. The clinical diagnosis was non-segmental vitiligo for at least 3 months.
    2. Involvement of BSA≥5%.
    3. Facial involvement BSA≥0.5%.
    4. F-VASI≥0.5 and T-VASI between 5 and 50.
    5. Active or stable non-segmental vitiligo was present at both screening and baseline visits.
  3. Women of (WOCBP) and Men must agree to .
  4. Before beginning any screening or study specific procedures, subjects must voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  1. Any of the following vitiligo related medical conditions and other skin diseases/conditions.

    a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2.

  2. History of any clinically major diseases, with the exception of vitiligo.
  3. Pregnant or breastfeeding females.
  4. The investigator considers that the subject is not suitable for participation in this study for any reason.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
603 participants (estimated)

Study arms

  • Experimental
    ICP-332 dose A(Phase2)

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo(Phase2)

    Drug: ICP-332 Placebo Tablets

  • Experimental
    ICP-332 dose B(Phase2:)

    Drug: ICP-332 Tablets

  • Experimental
    ICP-332 dose A or dose B(Phase3)

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo(Phase3)

    Drug: ICP-332 Placebo Tablets

Interventions

  • ICP-332 will be administered as tablet

  • DrugICP-332 Placebo Tablets

    ICP-332 Placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Phase2: Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24.

    Time frame: 24 weeks

  2. Phase3: Proportion of subjects achieving F-VASI 75 at Week 52.

    Time frame: 52 weeks

07

Study locations

4 of 45 sites recruiting
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241001, China
    Not yet recruiting
    • Chao Ci · Contact
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
    Not yet recruiting
    • Ruzhi Zhang · Contact
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Not yet recruiting
    • Chunlei Zhang · Contact
  • Beijing Chao-yang Hospital,Capital Medical University
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Fang Liu · Contact
  • Beijing Tongren Hospital
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Aihua Wei · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Not yet recruiting
    • Bin Wei · Contact
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400021, China
    Recruiting
    • Qingchun 400000 Diao · Contact
  • Union Hospital affiliated to Fujian Medical
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Huichun Su · Contact
  • The First Affiliated Hospital of Fujian Medical
    Fuzhou, Fujian 350005, China
    Not yet recruiting
    • Niu Xiang · Contact
  • Sun Yat-sen Memorial Hospital,Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
    Not yet recruiting
    • Liangchun Wang · Contact
  • Deramatology Hospital of Southern Medical Univercity
    Guangzhou, Guangdong 516006, China
    Not yet recruiting
    • Xiaowei Shi · Contact
  • Nanfang Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yue Zheng · Contact
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
    Not yet recruiting
    • Yanling Li · Contact
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Not yet recruiting
    • Bin Zhang · Contact
  • Nanyang First People's Hospital
    Nanyang, Henan 473000, China
    Not yet recruiting
    • Rixin Chen · Contact
  • The First Affiliated Hospital of Xinxiang Medical College
    Weihui, Henan 453100, China
    Not yet recruiting
    • Dandan Fu · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Jianguo Li · Contact
  • Zhengzhou Central Hospital Affiliated to Zhengzhou University
    Zhengzhou, Henan, China
    Not yet recruiting
    • Zixue Chen · Contact
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Not yet recruiting
    • Yi Sun · Contact
  • Shiyan People's Hospital
    Shiyan, Hubei, China
    Not yet recruiting
    • Zudong Meng · Contact
  • Wuhan NO.1 Hospital(Wuhan Hospital of Traditional Chinese and Western Medicine)
    Wuhan, Hubei 430022, China
    Not yet recruiting
    • Liuqing Chen · Contact
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Juan Li · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    Not yet recruiting
    • Yunsheng Liang · Contact
  • The First Affiliated Hospital of University Of South China
    Hengyang, Hunan, China
    Not yet recruiting
    • Zhijun Liu · Contact
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222061, China
    Not yet recruiting
    • Hong Ren · Contact
  • Hospital for Skin Diseases, Chinese Academy of Medical Sciences
    Nanjing, Jiangsu 210042, China
    Not yet recruiting
    • Qianjin Lu · Contact
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
    Not yet recruiting
    • Jun Gu · Contact
  • Dermatology hospital of jiangxi province
    Nanchang, Jiangxi 330000, China
    Not yet recruiting
    • Xiaoyi Wen · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Not yet recruiting
    • Xianwei Cao · Contact
  • The first hospital of Jilin Univercity
    Changchun, Jilin 130021, China
    Not yet recruiting
    • Shanshan Li · Contact
  • Shenyang Medical College Affiliated Central Hospital
    Shenyang, Liaoning, China
    Not yet recruiting
    • Xiaodong Li · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Yin Li · Contact
  • Shandong First Medical University Affiliated Dermatology Hospital (Shandong Institute of Dermatology and Venereology, Shandong Dermatology Hospital)
    Jinan, Shandong 250022, China
    Not yet recruiting
    • Furen Zhang · Contact
  • Zibo Central Hospital
    Zibo, Shandong, China
    Not yet recruiting
    • Guowei Zhao · Contact
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
    Recruiting
    • Folra Xiang · Contact
  • Shanghai Dermatology Hospital
    Shanghai, Shanghai Municipality 200050, China
    Not yet recruiting
    • Yangfeng Ding · Contact
  • Shaanxi Provincial People's Hospital
    Xian, Shanxi 710068, China
    Not yet recruiting
    • Li Yang · Contact
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610021, China
    Not yet recruiting
    • Yanping Feng · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Not yet recruiting
    • Lixia Zhang · Contact
  • The First Affiliated Hospital Of Kunming Medical University
    Kunming, Yunnan 650032, China
    Not yet recruiting
    • Dongjie Sun · Contact
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Aie Xu · Contact
  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Liming Wu · Contact
  • The First Affiliated Hospital Of Ningbo University
    Ningbo, Zhejiang 315100, China
    Not yet recruiting
    • Bingjiang Lin · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Not yet recruiting
    • Zhiming Li · Contact
  • The Fourth Affiliated Hospital, Zhejiang University School Of Medicine
    Yiwu, Zhejiang 322000, China
    Not yet recruiting
    • Lunfei Liu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Apr 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 2, 2025
StartActual
May 9, 2025
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07047612
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
May 9, 2025
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Aug 7, 2025

Study contacts

Flora Xiang, Doctor
Contact
flora_xiang@vip.163.com
021-52887775

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion